Does Medicare Advantage Cover AndroGel?

How Medicare Advantage Plans Handle AndroGel Coverage

Medicare Advantage (MA) plans with Part D prescription drug benefits can cover AndroGel when it is prescribed for an FDA-approved indication. The only FDA-approved indication for AndroGel 1.62% is replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone, collectively called male hypogonadism 1.

Each MA carrier (UnitedHealthcare, Humana, Aetna, Cigna, Anthem BCBS, and others) maintains its own Part D formulary, but CMS regulations set the floor. All Part D sponsors must cover at least two drugs per therapeutic class, and testosterone replacement products fall under the "androgens" class. Because generic testosterone gels now exist, carriers have flexibility to place brand-name AndroGel on higher tiers or impose additional utilization management. A 2020 CMS analysis found that 94% of Part D plans applied some form of utilization management to brand-name testosterone gels 2.

The practical result: coverage is available, but you will almost certainly face prior authorization, possible step therapy, and tier-based cost sharing that varies widely by carrier and plan year.

Prior Authorization Criteria for AndroGel on Medicare Advantage

Prior authorization is the single biggest barrier between a prescription and pharmacy pickup. Almost every MA plan requires it for brand-name AndroGel.

The PA criteria across major MA carriers follow a consistent pattern rooted in the Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism 3. To meet approval, your prescriber typically must document:

1. Diagnosis of male hypogonadism (primary or secondary) confirmed by clinical signs and symptoms such as decreased libido, erectile dysfunction, fatigue, loss of muscle mass, or depressed mood.

2. Two morning serum total testosterone measurements below 300 ng/dL (10.4 nmol/L), drawn before 10:00 AM on separate days. Some plans accept a threshold of 250 ng/dL. The Endocrine Society guideline recommends repeating a low value because testosterone levels fluctuate significantly day to day 3.

3. Exclusion of reversible causes, including opioid use, uncontrolled diabetes, morbid obesity, or active pituitary pathology.

4. Documentation of step therapy failure if the plan requires trial of a generic formulation first.

Plans typically issue a decision within 72 hours for standard requests. Expedited requests (when delay could seriously harm the patient) require a decision within 24 hours under CMS rules. If your prescriber submits incomplete documentation, expect a denial on procedural grounds rather than medical grounds. That distinction matters at appeal.

Step Therapy Requirements Across Major Carriers

Step therapy means the plan requires you to try a lower-cost alternative before it will authorize the brand-name drug. For AndroGel, the most common step therapy sequence looks like this:

Step 1: Generic testosterone cypionate injection (intramuscular, typically 100 to 200 mg every one to two weeks). This costs MA plans roughly $30 to $50 per month. Many patients and prescribers prefer gel for steadier serum levels, but plans want documented injection trial first.

Step 2: Generic testosterone gel 1.62% (Teva's authorized generic of AndroGel). This product is bioequivalent and costs approximately $150 to $250 per month, significantly below brand AndroGel's $510 list price.

Step 3: Brand AndroGel 1.62%, approved only after documented failure, intolerance, or contraindication to Steps 1 and 2.

"Failure" can include inadequate testosterone normalization on appropriate doses, injection-site reactions, or inability to self-administer injections due to physical limitations. A 2016 analysis from the Testosterone Trials (TTrials) demonstrated that testosterone gel normalized levels in 75% of men with hypogonadism, confirming the gel formulation's clinical reliability 4.

Not all carriers enforce all three steps. UnitedHealthcare MA plans, for example, often allow direct access to generic gel while restricting only the brand. Humana plans have historically required injectable trial first. Check your specific plan's formulary by calling the number on your member ID card or searching the plan's online formulary tool.

What Formulary Tier Is AndroGel On?

Formulary tier placement determines your out-of-pocket cost. Here is the typical tier structure for testosterone products across MA plans:

Tier 1 (generic/preferred generic): Testosterone cypionate injection. Copay: $0 to $15.

Tier 2 (generic): Generic testosterone gel 1.62%. Copay: $20 to $60.

Tier 3 (preferred brand): Some plans place AndroGel here. Copay: $40 to $90.

Tier 4 (non-preferred brand): Many plans place AndroGel here instead. Copay: $80 to $150. Some plans apply coinsurance (25% to 33%) rather than a flat copay at this tier, which at a $510 list price would mean $127 to $168 per month before any manufacturer support.

Tier 5 (specialty): AndroGel does not meet the CMS specialty-tier threshold ($890 per month for 2026), so legitimate placement on this tier would be unusual.

The difference between Tier 3 and Tier 4 placement can mean $50 or more per fill. If your plan places AndroGel on Tier 4 but a competitor plan in your area places it on Tier 3, that is worth considering during Annual Enrollment Period (October 15 through December 7). The Medicare Plan Finder tool at medicare.gov lets you compare drug costs across MA plans in your ZIP code by entering your specific medications.

How to Appeal a Medicare Advantage Denial of AndroGel

A denial is not the end. CMS has built a structured, time-limited appeals process that gives you multiple chances.

Level 1: Plan Redetermination. File within 60 days of the denial. Submit a written appeal with your prescriber's letter of medical necessity explaining why brand AndroGel is specifically required (e.g., documented failure on generic gel, allergy to an inactive ingredient, or dosing considerations). The plan must decide within 7 calendar days (72 hours if expedited). Roughly 50% of Part D coverage denials are overturned at Level 1 according to CMS data from 2023 5.

Level 2: Independent Review Entity (IRE). If Level 1 fails, the plan automatically forwards the case (or you can request forwarding) to the IRE, currently MAXIMUS Federal Services. MAXIMUS reviews independently of the plan. They must decide within 7 calendar days. The overturn rate at IRE level runs approximately 30% to 40% for prescription drug appeals.

Level 3: Office of Medicare Hearings and Appeals (OMHA). Requires a minimum amount in controversy ($200 for 2026). This is an Administrative Law Judge hearing, typically by phone or video. Few AndroGel appeals reach this stage.

Level 4: Medicare Appeals Council. Reviews ALJ decisions.

Level 5: Federal District Court. Requires $1,840 minimum amount in controversy for 2026.

The strongest appeal letters include three elements: the specific clinical diagnosis with ICD-10 code (E29.1 for primary testicular hypofunction or E23.0 for secondary hypogonadism due to pituitary dysfunction), lab values with dates, and a clear statement of why the requested brand is medically necessary over available alternatives. Your prescriber should reference the Endocrine Society guideline recommendation that testosterone gel provides more physiologic, steady-state levels compared to intramuscular injection peaks and troughs 3.

AndroGel Costs With and Without Medicare Advantage Coverage

The financial picture varies dramatically depending on coverage status.

With MA coverage (Tier 3): $40 to $90 per 30-day supply, depending on plan design and whether you have reached the coverage gap (the "donut hole"). In 2025, the Inflation Reduction Act capped total Part D out-of-pocket spending at $2,000 annually, which provides a hard ceiling for high-cost medications 6. That cap continues in 2026.

With MA coverage (Tier 4): $80 to $150 per 30-day supply, or 25% to 33% coinsurance.

Without coverage (cash pay): Approximately $510 per month at list price. GoodRx and similar discount platforms may reduce this to $350 to $430 at select pharmacies.

Generic testosterone gel 1.62%: $80 to $180 per month cash, $20 to $60 with insurance. This is the same active ingredient, same concentration, same pump delivery. The FDA considers it therapeutically equivalent (AB-rated).

One critical note: the $2,000 annual Part D out-of-pocket cap means that even at Tier 4 pricing, your total yearly testosterone gel cost is capped. If you take other Part D medications, they all count toward the same $2,000 ceiling. For a patient taking AndroGel at $150 per month copay, the cap would be reached by month 14, making the remaining months of the year effectively free. But this math resets each January 1.

Why Medicare Advantage Does Not Cover AndroGel for Weight Loss

This distinction is absolute. CMS explicitly excludes weight loss from covered Part D indications for testosterone products. The statutory language in Section 1862(a)(1)(A) of the Social Security Act, reinforced by CMS guidance, bars Part D coverage for drugs "used for anorexia, weight loss, or weight gain" unless the drug carries an FDA-approved indication for a cardiovascular outcome (as semaglutide did after its March 2024 MACE indication for Wegovy) 7.

AndroGel's FDA label is specific to male hypogonadism. While testosterone replacement can shift body composition, reducing fat mass and increasing lean mass (the TTrials showed a mean 2.6% reduction in fat mass over 12 months with testosterone gel) 4, this is a secondary metabolic effect, not an approved weight-loss indication.

If a prescriber submits a prior authorization citing weight management or obesity as the primary diagnosis, the claim will be denied. The correct approach: diagnose and document the underlying hypogonadism with appropriate lab values, then note body composition changes as a monitored secondary outcome.

Comparing AndroGel to Covered Testosterone Alternatives on Medicare Advantage

When brand AndroGel is denied or cost-prohibitive, several alternatives may offer better coverage:

Testosterone cypionate injection (generic): Tier 1 on most MA plans. Cost: $0 to $15 copay. Requires intramuscular injection every 1 to 2 weeks. Produces peak-trough fluctuations in serum testosterone that some men find uncomfortable. The Endocrine Society notes that injection schedules can be adjusted to minimize this variability 3.

Generic testosterone gel 1.62% (Teva): Tier 2 on most plans. Cost: $20 to $60 copay. Bioequivalent to brand AndroGel. Applied daily to upper arms or shoulders. Requires attention to skin-to-skin transfer risk.

Testosterone patch (Androderm): Tier 3 or 4. Cost: $60 to $120 copay. Application-site skin reactions occur in up to 37% of users according to prescribing information, making it less tolerable than gel for many patients 8.

Testosterone nasal gel (Natesto): Tier 4 or non-formulary on most MA plans. Cost: $100 to $200 copay. Applied three times daily intranasally. May preserve fertility better than other testosterone formulations based on preliminary data, but the dosing frequency is a barrier for many men.

Oral testosterone undecanoate (Jatenzo): Tier 4 or 5, or excluded from formulary. Cost: $150+ copay. Taken twice daily with food. Carries an FDA boxed warning for blood pressure increases 9.

For most MA beneficiaries, generic testosterone gel provides the closest clinical experience to brand AndroGel at one-third to one-half the copay.

Monitoring Requirements That Affect Ongoing Coverage

MA plans do not just authorize AndroGel once and forget it. Most prior authorizations are valid for 6 to 12 months, after which re-authorization is required. Your prescriber will need to document:

Serum testosterone levels checked 2 to 4 weeks after initiation or dose adjustment, then every 6 to 12 months. Target range: 450 to 600 ng/dL mid-range, measured 2 to 8 hours after gel application 3.

Hematocrit checked at baseline, 3 to 6 months, then annually. Testosterone therapy raises red blood cell production. The Endocrine Society recommends dose reduction or temporary discontinuation if hematocrit exceeds 54% due to increased venous thromboembolism risk 3.

PSA (prostate-specific antigen) at baseline and 3 to 12 months after starting therapy. Testosterone is contraindicated in men with known prostate cancer. The AUA/Endocrine Society recommend referral to urology if PSA rises more than 1.4 ng/mL within 12 months of starting therapy 10.

Lipid panel and metabolic markers annually. The TTrials found no significant adverse cardiovascular events over the 12-month treatment period, but longer-term monitoring remains standard practice 4.

Missing these labs can result in re-authorization denial. Set calendar reminders or work with your prescriber's office to schedule them proactively before the PA renewal date.

The Manufacturer Savings Card Question for Medicare Beneficiaries

Federal law prohibits Medicare beneficiaries from using manufacturer copay cards or savings programs. The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) makes it illegal for pharmaceutical manufacturers to offer financial incentives that could influence a federal healthcare beneficiary's choice of medication. AbbVie's AndroGel savings card explicitly states on its terms that it is "not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs" 11.

This restriction applies to all MA plans, original Medicare Part D, Medicaid managed care, TRICARE, and VA benefits. The only exception: manufacturer Patient Assistance Programs (PAPs) that provide free medication to qualifying low-income patients are generally permitted because the patient pays nothing (removing the kickback element). AbbVie operates a patient assistance program; eligibility typically requires income below 200% of the Federal Poverty Level.